Understanding LSM12: A Potential Drug Target for Neurotransmission and Inflammation

Target Name: LSM12

NCBI ID: G124801

LSM12

Understanding LSM12: A Potential Drug Target for Neurotransmission and Inflammation

LSM12 (LSM12 homolog) is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a member of the LSM12 family, which is characterized by the presence of a unique nucleotide-binding oligomerization domain (NBD) in the protein.

The NBD is a structural motif that is composed of a nucleotide-binding domain and a hydrophobic tail. The NBD is responsible for the protein's stability and functions as a scaffold to recruit other proteins to the NBD-containing region of the protein.

LSM12 is involved in a variety of cellular processes, including cell signaling, cell adhesion, and inflammation. It has been shown to play a role in the regulation of neurotransmitter release from axons, which are the projection neurons that carry signals from the brain to the rest of the body.

In addition to its role in neurotransmission, LSM12 is also involved in the regulation of inflammation. It has been shown to play a role in the development of neuroinflammation, which is characterized by inflammation in the brain and other central nervous system (CNS) tissues.

Despite its involvement in a variety of cellular processes, LSM12 is not well understood, and there is limited research on its potential as a drug target or biomarker. However, its unique NBD-containing structure and its involvement in neurotransmission and inflammation make it an attractive candidate for further research.

One potential mechanism by which LSM12 could be targeted as a drug or biomarker is its role in the regulation of neurotransmission. By modulating the activity of LSM12, researchers could potentially interfere with neurotransmission and treat a variety of neurological and psychiatric disorders. For example, LSM12 has been shown to play a role in the regulation of the release of neurotransmitters such as dopamine and serotonin, which are involved in a variety of neurological disorders, including Parkinson's disease and depression.

Another potential mechanism by which LSM12 could be targeted as a drug or biomarker is its role in the regulation of inflammation. LSM12 has been shown to play a role in the development of neuroinflammation, which is characterized by inflammation in the brain and other CNS tissues. By targeting LSM12 with drugs or other therapeutic agents, researchers could potentially treat a variety of inflammatory neurological disorders.

In conclusion, LSM12 is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a member of the LSM12 family and is involved in a variety of cellular processes, including cell signaling, cell adhesion, and inflammation. Despite its involvement in these processes, LSM12 is not well understood, and there is limited research on its potential as a drug target or biomarker. Further research is needed to fully understand the role of LSM12 in cellular processes and its potential as a therapeutic agent.

Protein Name: LSM12 Homolog

Functions: Nicotinic acid adenine dinucleotide phosphate (NAADP) binding protein (PubMed:34362892). Confers NAADP sensitivity to the two pore channel complex (TPCs) by acting as TPC accessory protein necessary for NAADP-evoked Ca(2+) release (PubMed:34362892)

The "LSM12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LSM12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets